Bacteriofages in the Medicinal Treatment of Odontogenic Flagmones in the Main and Sublanguage Areas
Keywords:
odontogenic phlegmon, submandibular region, sublingual region, bacteriophages, phago therapy, antibiotic resistance, biofilmAbstract
The work provides an analytical review of modern data on the use of bacteriophages in the complex pharmacological treatment of odontogenic phlegmons of the mandibular and sublingual regions. The mechanisms of lytic activity of bacteriophages, their ability to destroy capsular structures and biofilms, as well as the potentiation of antibiotic action, have been examined. Particular attention is paid to the phage sensitivity of clinically significant microorganisms and the prospects for individualized selection of phage preparations.
References
[1] S. Kh. Alimova, Zh. Sh. Patkhiddinov, and K. Z. Adilov, “Use of preparations with bacteriophages in the treatment of inflammatory periodontal diseases,” Stomatology - science and practice, development prospects, Volga State Medical University Conference, pp. 33–34, 2018.
[2] A. G. Afinogenova, G. E. Afinogenov, M. I. Gordeev, and D. Yu. Madai, “Method for assessing the specific activity of bacteriophages,” Problems of Medical Mycology, vol. 16, no. 2, p. 39, 2014.
[3] I. A. Ivanova et al., “Bacteriophages and the immune system of the macroorganism: review,” Journal of Microbiology, Epidemiology, and Immunobiology, no. 6, pp. 79–84, 2019.
[4] N. I. Briko et al., “Frequency of diseases caused by group A streptococci among invasive infections of soft tissues,” Journal of Microbiology, Epidemiology, and Immunobiology, no. 5, pp. 24–31, 2014.
[5] A. A. Vakarina, L. V. Katayeva, and T. F. Stepanova, “Influence of bacteriophages on the sensitivity of conditionally pathogenic bacteria to antibacterial drugs,” Journal of Microbiology, Epidemiology, and Immunobiology, no. 2, pp. 3–7, 2019.
[6] A. A. Vakarina, L. V. Katayeva, and N. F. Karpukhina, “Rational aspects of using bacteriophages,” Journal of Microbiology, Epidemiology, and Immunobiology, no. 5, pp. 76–79, 2015.
[7] E. V. Voitenkova and L. V. Suzhaeva, “Sensitivity of Staphylococcus aureus to bacteriophages,” Problems of Medical Mycology, vol. 23, no. 2, pp. 66–67, 2021.
[8] E. A. Volkov, M. L. Polovets et al., “Effectiveness of using a bacteriophage-based agent in complex treatment of oral mucosal diseases,” Russian Dental Journal, vol. 19, no. 4, pp. 18–22, 2015.
[9] E. A. Denisenko et al., “Genomic analysis of bacteriophages with lytic activity against Escherichia coli,” Problems of Medical Mycology, vol. 23, no. 2, pp. 73–74, 2021.
[10] A. S. Gorshkova, V. V. Drucker, and N. N. Sykilinda, “Joint action of bacteriophages and antibiotics on biofilm of Pseudomonas aeruginosa,” Antibiotics and Chemotherapy, vol. 65, no. 3–4, pp. 7–11, 2020.
[11] S. T. Abedon, “Phage therapy of pulmonary infections,” Bacteriophage, vol. 5, no. 1, e1020260, 2015.
[12] O. Adesanya et al., “Exegesis of phage therapy: a developing participant in antimicrobial resistance fight,” AIMS Microbiology, vol. 6, no. 3, pp. 204–230, 2020.
[13] S. Aslam et al., “Early clinical experience of phage therapy in lung transplant recipients,” American Journal of Transplantation, vol. 19, no. 9, pp. 2631–2639, 2019.
[14] H. B. Erol et al., “Treatment of root canal biofilms associated with Enterococcus faecalis using phage therapy,” Microbial Pathogenesis, vol. 197, 107081, 2024.
[15] M. K. Birt, D. V. Anderson, E. B. Toby, and J. Wang, “Osteomyelitis: modern therapeutic strategies,” Journal of Orthopaedics, vol. 14, no. 1, pp. 45–52, 2016.
[16] S. Cao et al., “Engineering bacteriophages in anti-infectious and anti-tumor therapy,” Microbial Pathogenesis, vol. 198, 107052, 2025.
